乳腺癌免疫逃逸机理的研究进展_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

孙正魁 , 姚榛祥

Corresponding author：

Keywords：

乳腺癌; 免疫逃逸; T淋巴细胞

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的综述乳腺癌细胞逃避机体免疫监视机理的研究进展。
方法复习国内、外相关文献，从主要组织相容性抗原复合物（MHC）Ⅰ类分子表型改变、缺乏共刺激信号、肿瘤表达FasL、人类TNF相关凋亡诱导配体（TRAIL）的杀伤作用以及肿瘤抗原诱导机体免疫耐受几个方面对乳腺癌免疫逃逸机理的研究进展加以综述。
结果 MHCⅠ类分子表型改变,共刺激分子B7缺乏,肿瘤细胞表达FasL和TRAIL, 以及肿瘤抗原诱导机体免疫耐受与乳腺癌免疫逃逸有关。
结论乳腺癌细胞通过自身抗原改变、不表达共刺激分子、诱导机体T淋巴细胞凋亡和机体免疫耐受而逃避机体免疫监视，但对其免疫逃逸机理中各种因素的相互影响和综合作用尚未被充分认识。

Citation： 孙正魁,姚榛祥. 乳腺癌免疫逃逸机理的研究进展. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(1): 26-28. doi: Copy

1.	Meazza R, Gaggero A, Neglia F, et al. Expression of two interleukin15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides [J]. Eur J Immunol, 1997; 27(5)∶1049.
2.	Carosella ED, RouasFreiss N, Paul P, et al. HLAG: a tolerance molecule from the major histocompatibility complex [J]. Immunol Today, 1999; 20(2)∶60.
3.	D’Orazio TJ, Niederkorn JY. A novel role for TGFbeta and IL10 in the induction of immune privilege [J]. J Immunol, 1998; 160(5)∶2089.
4.	SalazarOnfray F. Interleukin10： a cytokine used by tumors to escape immunosurveillance [J]. Med Oncol, 1999; 16(2)∶86.
5.	Chouaib S, AsselinPaturel C, MamiChouaib F, et al. The hosttumor immune conflict: from immunosuppression to resistance and destruction [J]. Immunol Today, 1997; 18(10)∶493.
6.	Matsni S, Ahlers JD, Vortmeyer AO, et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL [J]. J Immunol, 1999; 163(1)∶184.
7.	Adler AJ, Marsh DW, Yochum GS, et al. CD4+ T cell tolerance to parenchymal selfantigens requires presentation by bone marrowderived antigenpresenting cells [J]. J Exp Med, 1998; 187(10)∶1555.
8.	O’Connell J, Bennett MW, O’Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege [J]. Immunol Today, 1999; 20(1)∶46.
9.	Zia A, Schildberg FM, Funke I. MHC classⅠnegative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in ROMO breast cancer patients [J]. Int J Cancer, 2001; 93(4)∶566.
10.	Feinmesser M, Sulkes A, Morgenstern S, et al. HLADR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities [J]. J Clin Pathol, 2000; 53(4)∶286.
11.	Lefebvre S, Antoine M, Uzan S, et al. Specific activation of the nonclassical class Ⅰ histocompatibility HLAG antigen and expression of the ILT2 inhibitory receptor in human breast cancer [J]. J Pathol, 2002; 196(3)∶266.
12.	Emtage PC, Wan Y, Bramson JL, et al. A double recombinant adenovirus expressing the costimulatory molecule B71 (murine) and human IL2 induces complete tumor regression in a murine breast adenocarcinoma model [J]. J Immunol, 1998; 160(5)∶2531.
13.	Emtage PC, Wan Y, Muller W, et al. Enhanced interleukin2 gene transfer immunotherapy of breast cancer by coexpression of B71 and B72 [J]. J Interferon Cytokine Res, 1998; 18(11)∶927.
14.	Giovarelli M, Musiani P, Garotta G, et al. A “stealth effect”: adenocarcinoma cells engineered to express TRAIL elude tumorspecific and allogeneic T cell reactions [J]. J Immunol, 1999; 163(9)∶4886.
15.	Herrnring C, Reimer T, Jeschke U,et al. Expression of the apoptosisinducing ligands FasL and TRAIL in malignant and benign human breast tumors [J]. Histochem Cell Biol, 2000; 113(3)∶189.
16.	O’Connell J, Bennett MW, O’Sullivan GC, et al. Expression of Fas (CD95/APO1) ligand by human breast cancers: significance for tumor immune privilege [J]. Clin Diagn Lab Immunol, 1999; 6(4)∶457.
17.	Gutierrez LS, Eliza M, NivenFairchild T, et al. The Fas/Fasligand system: a mechanism for immune evasion in human breast carcinomas [J]. Breast Cancer Res Treat, 1999; 54(3)∶245.
18.	Muschen M, Moers C, Warskulat U, et al. CD95 ligand expression in dedifferentiated breast cancer [J]. J Pathol, 1999; 189(3)∶378.
19.	Muschen M, Moers C, Warskulat U, et al. CD95 ligand expression as a mechanism of immune escape in breast cancer [J]. Immunology, 2000; 99(1)∶69.
20.	Kurt RA, Whitaker R, Baher A, et al. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice [J]. Int J Cancer, 2000; 87(5)∶688.

1. Meazza R, Gaggero A, Neglia F, et al. Expression of two interleukin15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides [J]. Eur J Immunol, 1997; 27(5)∶1049.
2. Carosella ED, RouasFreiss N, Paul P, et al. HLAG: a tolerance molecule from the major histocompatibility complex [J]. Immunol Today, 1999; 20(2)∶60.
3. D’Orazio TJ, Niederkorn JY. A novel role for TGFbeta and IL10 in the induction of immune privilege [J]. J Immunol, 1998; 160(5)∶2089.
4. SalazarOnfray F. Interleukin10： a cytokine used by tumors to escape immunosurveillance [J]. Med Oncol, 1999; 16(2)∶86.
5. Chouaib S, AsselinPaturel C, MamiChouaib F, et al. The hosttumor immune conflict: from immunosuppression to resistance and destruction [J]. Immunol Today, 1997; 18(10)∶493.
6. Matsni S, Ahlers JD, Vortmeyer AO, et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL [J]. J Immunol, 1999; 163(1)∶184.
7. Adler AJ, Marsh DW, Yochum GS, et al. CD4+ T cell tolerance to parenchymal selfantigens requires presentation by bone marrowderived antigenpresenting cells [J]. J Exp Med, 1998; 187(10)∶1555.
8. O’Connell J, Bennett MW, O’Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege [J]. Immunol Today, 1999; 20(1)∶46.
9. Zia A, Schildberg FM, Funke I. MHC classⅠnegative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in ROMO breast cancer patients [J]. Int J Cancer, 2001; 93(4)∶566.
10. Feinmesser M, Sulkes A, Morgenstern S, et al. HLADR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities [J]. J Clin Pathol, 2000; 53(4)∶286.
11. Lefebvre S, Antoine M, Uzan S, et al. Specific activation of the nonclassical class Ⅰ histocompatibility HLAG antigen and expression of the ILT2 inhibitory receptor in human breast cancer [J]. J Pathol, 2002; 196(3)∶266.
12. Emtage PC, Wan Y, Bramson JL, et al. A double recombinant adenovirus expressing the costimulatory molecule B71 (murine) and human IL2 induces complete tumor regression in a murine breast adenocarcinoma model [J]. J Immunol, 1998; 160(5)∶2531.
13. Emtage PC, Wan Y, Muller W, et al. Enhanced interleukin2 gene transfer immunotherapy of breast cancer by coexpression of B71 and B72 [J]. J Interferon Cytokine Res, 1998; 18(11)∶927.
14. Giovarelli M, Musiani P, Garotta G, et al. A “stealth effect”: adenocarcinoma cells engineered to express TRAIL elude tumorspecific and allogeneic T cell reactions [J]. J Immunol, 1999; 163(9)∶4886.
15. Herrnring C, Reimer T, Jeschke U,et al. Expression of the apoptosisinducing ligands FasL and TRAIL in malignant and benign human breast tumors [J]. Histochem Cell Biol, 2000; 113(3)∶189.
16. O’Connell J, Bennett MW, O’Sullivan GC, et al. Expression of Fas (CD95/APO1) ligand by human breast cancers: significance for tumor immune privilege [J]. Clin Diagn Lab Immunol, 1999; 6(4)∶457.
17. Gutierrez LS, Eliza M, NivenFairchild T, et al. The Fas/Fasligand system: a mechanism for immune evasion in human breast carcinomas [J]. Breast Cancer Res Treat, 1999; 54(3)∶245.
18. Muschen M, Moers C, Warskulat U, et al. CD95 ligand expression in dedifferentiated breast cancer [J]. J Pathol, 1999; 189(3)∶378.
19. Muschen M, Moers C, Warskulat U, et al. CD95 ligand expression as a mechanism of immune escape in breast cancer [J]. Immunology, 2000; 99(1)∶69.
20. Kurt RA, Whitaker R, Baher A, et al. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice [J]. Int J Cancer, 2000; 87(5)∶688.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

乳腺癌免疫逃逸机理的研究进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content